← Leaderboards
Susan E. Crawford
Northwestern University
$4,042,445
Attributed
$5,701,361
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $633.8K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$5,701,361 · 4
By mechanism
R01$4,804,867 · 2
P30$611,098 · 1
R21$285,396 · 1
Top collaborators
- Vadim Backman4 shared
- Hemant K Roy4 shared
Most similar at Northwestern University
Same institution · by research overlap
- Vadim Backman$34,873,053
- Hariharan Subramanian$1,672,189
- Janardan K. Reddy$8,750,751
- Seema Ahsan Khan$17,558,735
- Vadim Backman$5,238,271
Others in their field
Top investigators on “Phenotype”
- David R. Weir · University Of Michigan At Ann Arbor$239,033,262
- David Heimbrook · Leidos Biomedical Research, Inc.$213,586,034
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$184,906,270
- James E. Gern · University Of Wisconsin-Madison$141,704,104
- Garret A Fitzgerald · University Of Pennsylvania$141,348,491
Research focus
PhenotypeTumorHuman TissueAnimalsOrganBody SystemProteinsResearch PersonnelAngiogenesisLiverProstateLesionLiver NeoplasmsEpithelialPigment Epithelium-Derived FactorIntestinesHistologyGrowthPathologicPathologistFutureGene ExpressionBaseMolecular
Grant awards (23)
Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology$603,868
R01 · FY2019 · CA
Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology$628,861
R01 · FY2018 · CA
Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology$633,774
R01 · FY2017 · CA
Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology$621,871
R01 · FY2016 · CA
mouse phenotyping$161,721
P30 · FY2012 · CA · contact PI
mouse phenotyping$87,923
P30 · FY2011 · CA · contact PI
Anti-angiogenic Barriers to Tumor Development$262,838
R01 · FY2010 · CA · contact PI
mouse phenotyping$92,250
P30 · FY2010 · CA · contact PI
Anti-angiogenic Barriers to Tumor Development$262,838
R01 · FY2009 · CA · contact PI
mouse phenotyping$94,348
P30 · FY2009 · CA · contact PI
Anti-angiogenic Barriers to Tumor Development$167,750
R01 · FY2008 · CA · contact PI
Anti-angiogenic Barriers to Tumor Development$94,153
R01 · FY2008 · CA · contact PI
mouse phenotyping$93,774
P30 · FY2008 · CA · contact PI
Anti-angiogenic Barriers to Tumor Development$260,253
R01 · FY2007 · CA · contact PI
mouse phenotyping$81,082
P30 · FY2007 · CA · contact PI
Anti-angiogenic Barriers to Tumor Development$268,025
R01 · FY2006 · CA · contact PI
ANTIANGIOGENIC BARRIERS TO TUMOR DEVELOPMENT$66,655
R01 · FY2005 · CA
Thrombospondin-1 in prostate development and neoplasia$142,680
R21 · FY2004 · CA
ANTIANGIOGENIC BARRIERS TO TUMOR DEVELOPMENT$318,651
R01 · FY2003 · CA
Thrombospondin-1 in prostate development and neoplasia$142,716
R21 · FY2003 · CA
ANTIANGIOGENIC BARRIERS TO TUMOR DEVELOPMENT$309,372
R01 · FY2002 · CA
ANTIANGIOGENIC BARRIERS TO TUMOR DEVELOPMENT$300,362
R01 · FY2001 · CA
ANTIANGIOGENIC BARRIERS TO TUMOR DEVELOPMENT$5,596
R01 · FY2001 · CA